CASI Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

16.08.24	CASI Pharmaceuticals, Inc. Q2 Loss Declines (RTTNews)
08.07.24	CASI Pharmaceuticals Appoints Daniel Lang As CFO (RTTNews)
27.06.24	CASI Pharma Receives Acquisition Proposal For Entire China Business; Stock Surges In After-hours (RTTNews)
28.03.24	Recap: CASI Pharmaceuticals Q4 Earnings (Benzinga)
05.03.24	CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients (Benzinga)
05.03.24	CASI Pharma Posts Positive BI-1206 Interim Phase 1 Data In R/R INHL; Stock Climbs In Pre-market (RTTNews)
14.11.23	CASI Pharmaceuticals Posts Narrower Loss In Q3 (RTTNews)
14.11.23	CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES (PR Newswire)
08.11.23	CASI : Juventas' CNCT 19 Approved In China For R/R B-cell Acute Lymphoblastic Leukemia Treatment (RTTNews)
08.11.23	CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA (PR Newswire)
11.08.23	CASI Pharmaceuticals, Inc. Q2 Loss Widens (RTTNews)
11.08.23	CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES (PR Newswire)
01.08.23	Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals (PR Newswire)
20.07.23	CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 (PR Newswire)
17.05.23	CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
26.04.23	CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022 (PR Newswire)
26.04.23	CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS (PR Newswire)
21.03.23	CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER (PR Newswire)
06.01.23	CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA (PR Newswire)
15.12.22	CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (PR Newswire)
14.11.22	CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
23.09.22	CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET (PR Newswire)
07.09.22	CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA (PR Newswire)
12.08.22	CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
05.08.22	CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022 (PR Newswire)
08.07.22	CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION (PR Newswire)
26.05.22	CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT (PR Newswire)
24.05.22	CASI Pharma Inks Sublicense Agreement With Beijing Tianshi For CID-103 (RTTNews)
24.05.22	CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE FIELD (PR Newswire)
12.05.22	CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
12.05.22	Ausblick: CASI Pharmaceuticals stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
02.05.22	CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022 (PR Newswire)
01.04.22	CASI PHARMACEUTICALS STATEMENT ON STATUS UNDER HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT (PR Newswire)
28.03.22	CASI PHARMACEUTICALS ANNOUNCES FULL-YEAR 2021 FINANCIAL RESULTS AND FOURTH QUARTER 2021 EVOMELA® REVENUE (PR Newswire)
27.03.22	Ausblick: CASI Pharmaceuticals legt Zahlen zum jüngsten Quartal vor (finanzen.net)
23.03.22	CASI PHARMACEUTICALS TO REPORT FOURTH QUARTER AND YEAR END 2021 FINANCIAL RESULTS AND HOST CONFERENCE CALL MARCH 28, 2022 (PR Newswire)
04.03.22	CASI PHARMACEUTICALS ANNOUNCES RENEWAL OF EXCLUSIVE DISTRIBUTION AGREEMENT FOR EVOMELA® IN CHINA (PR Newswire)
16.02.22	CASI PHARMACEUTICALS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL-YEAR 2021 REVENUES AND PROVIDES BUSINESS UPDATES (PR Newswire)
20.01.22	CASI Pharma: Bi-1206 Granted Orphan Drug Designation By FDA For Follicular Lymphoma Treatment (RTTNews)
20.01.22	CASI PHARMACEUTICALS PARTNER, BIOINVENT, ANNOUNCES BI -1206 GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (PR Newswire)
18.01.22	CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA (PR Newswire)
03.01.22	CASI PHARMACEUTICALS, RECEIVES NASDAQ DEFICIENCY NOTICE (PR Newswire)
17.12.21	CASI PHARMACEUTICALS ANNOUNCES STOCK REPURCHASE PROGRAM (PR Newswire)
10.12.21	CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE CTA APPROVAL FOR CLINICAL STUDY OF BI-1206 IN NHL IN CHINA (PR Newswire)
15.11.21	CASI Pharmaceuticals To Present At Jefferies London Healthcare Conference (PR Newswire)
12.11.21	CASI Pharmaceuticals Announces Third Quarter 2021 Financial Results (PR Newswire)
11.11.21	Ausblick: CASI Pharmaceuticals veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
05.11.21	CASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On BI-1206 At ASH 2021 (PR Newswire)
02.11.21	CASI Pharmaceuticals To Report Third Quarter 2021 Financial Results And Host Conference Call November 12, 2021 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Geberit	510.00	3.09 %	K V
UBS Group	29.96	1.97 %	K V
Zurich Insur Gr	537.60	1.55 %	K V
Logitech Intl	80.34	1.47 %	K V
Swiss Life Hldg	717.00	1.36 %	K V
Kuehne+Nagel Int	200.90	0.45 %	K V
Swisscom	509.00	0.30 %	K V
Alcon	75.84	0.18 %	K V
Nestle	73.66	-0.67 %	K V
CieFinRichemont	139.05	-0.82 %	K V

Nachrichten zu CASI Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten